Market Place
Sourcing Support
Kaleido cuts staff, halts COPD work and COVID program disappears
29 Jan 2022 //
FIERCEBIOTECH
Kaleido Biosciences to Present Updated Data of KB295 In Ulcerative Colitis
21 Jan 2022 //
GLOBENEWSWIRE
Kaleido Biosciences Announces New Clinical and Preclinical Data of KB295
05 Oct 2021 //
GLOBENEWSWIRE
Kaleido Biosciences to Host Virtual R&D Presentation to Discuss Clinical Data
29 Sep 2021 //
GLOBENEWSWIRE
Kaleido warned; FDA not persuaded by `medical food` claim
09 Sep 2021 //
RAPS
Glycans developer issued warning over failure to file IND in COVID-19 StudG
08 Sep 2021 //
NUTRAINGREDIENTS
Food or drug? FDA blasts microbiome player’s ‘non-IND’ Covid-19 trial
07 Sep 2021 //
ENDPTS
Kaleido Biosciences Receives FDA Warning Letter
26 Aug 2021 //
FDA
Kaleido Bio to Participate in 41st Annual Canaccord Genuity Growth Conference
06 Aug 2021 //
GLOBENEWSWIRE
Kaleido Biosciences Reports First Quarter 2021 Financial Results
04 May 2021 //
GLOBENEWSWIRE
Kaleido Biosciences says oral drug cuts COVID-19 recovery time, hospitalizations
24 Mar 2021 //
REUTERS
Kaleido Biosciences says oral drug cuts COVID-19 recovery time, hospitalizations
24 Mar 2021 //
REUTERS
Kaleido Biosciences Announces the Exercise of the Underwriters’ Option
11 Feb 2021 //
GLOBENEWSWIRE
Kaleido Biosciences Announces Proposed Public Offering of Common Stock
03 Feb 2021 //
GLOBENEWSWIRE
Kaleido Announces Positive Interim Results of Controlled Study of KB109
14 Jan 2021 //
GLOBENEWSWIRE
Kaleido Biosciences Announces Data from MMT Programs Accepted for Presentation
07 Oct 2020 //
GLOBENEWSWIRE
Kaleido Announces 1st Patient Dosed in Clinical Study of KB295
29 Sep 2020 //
GLOBENEWSWIRE
Kaleido Announces Presentation of Data for Microbiome Metabolic Therapy KB174
27 Aug 2020 //
GLOBENEWSWIRE
Kaleido Initiates Controlled Clinical Study Massachusetts General Hosp KB109
23 Jul 2020 //
GLOBENEWSWIRE
Kaleido Biosciences Announces Pricing of Public Offering of Common Stock
01 Jun 2020 //
GLOBENEWSWIRE
Kaleido`s to Advance KB174 for Hepatic Encephalopathy Based +ve Top-Line Results
13 Dec 2019 //
GLOBENESWIRE
Startup Dyne Therapeutics hires Kaleido exec as new chief
02 Oct 2019 //
FIERCE BIOTECH
Kaleido Bio Downsizes IPO, Raises $75M for Microbiome Drug Tests
28 Feb 2019 //
XCONOMY
Food-sourced microbiome drugs get $101M megaround for Flagship’s Kaleido
25 Jun 2018 //
ENDPTS
Kaleido Biosciences Emerges From Stealth Mode With $65 Million
18 Sep 2017 //
BIOSPACE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.